Overview

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

Summary

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).

Phase:

Phase 3

Details

Lead Sponsor:

European Myeloma Network

Collaborator:

Karyopharm Therapeutics Inc

Treatments:

Dexamethasone
Elotuzumab
Pomalidomide